Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients

NCT00562978 | Completed Phase 1 Results

• 5 other identifiers: 98153P30CA033572P01CA030206CHNMC-98153CDR0000574716
• Study Type: interventional
• Target: 54
• Locations: 0 countries
• Sites: N/A

Brief Summary

RATIONALE: Radiolabeled monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to kill cancer cells or stop them from growing. Giving radiolabeled monoclonal antibodies together with etoposide and cyclophosphamide before a peripheral blood stem cell transplant may be an effective treatment for non-Hodgkin lymphoma. PURPOSE: This phase I/II trial is studying the side effects and best dose of yttrium Y 90 ibritumomab tiuxetan when given together with etoposide and cyclophosphamide followed by an autologous stem cell transplant and to see how well it works in treating patients with non-Hodgkin lymphoma.

Conditions

Lymphoma

Keywords

recurrent grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma; recurrent grade 3 follicular lymphoma; recurrent adult diffuse large cell lymphoma; recurrent adult diffuse mixed cell lymphoma; recurrent adult diffuse small cleaved cell lymphoma; recurrent adult immunoblastic large cell lymphoma; recurrent mantle cell lymphoma; stage III grade 1 follicular lymphoma; stage III grade 2 follicular lymphoma; stage III grade 3 follicular lymphoma; stage IV grade 1 follicular lymphoma; stage IV grade 2 follicular lymphoma; stage IV grade 3 follicular lymphoma; stage III adult diffuse large cell lymphoma; stage III adult diffuse mixed cell lymphoma; stage III adult diffuse small cleaved cell lymphoma; stage IV adult diffuse large cell lymphoma; stage IV adult diffuse mixed cell lymphoma; stage IV adult diffuse small cleaved cell lymphoma; stage III mantle cell lymphoma; stage IV mantle cell lymphoma; stage III adult immunoblastic large cell lymphoma; stage IV adult immunoblastic large cell lymphoma

Outcome Measures

Primary Outcomes (4)

• Number of Patients Achieving Complete Response (CR)

  Complete response is defined as complete disappearance of all measureable evidence of non-evaluable disease. No new lesions. No disease related symptoms. No evidence of non-evaluable disease, including normalization of markers and other abnormal lab values. All measureable, evaluable and non-evaluable lesions and sites must be assessed using the same techniques as baseline.

  Assessed up to 5 years post-ASCT

• Number of Patients With Grade 3 or Greater Toxicity

  The NCI Common Toxicity Criteria (CTC Version 2.0) are used. The patients, whose toxicities are grade 3 or greater and at possibly related to the study treatment, are reported.

  From initial of study treatment to Day 100 post-ASCT

• 5-Year Overall Survival (Phase II)

  Overall survival (OS) was measured from peripheral stem cell infusion to death from any cause. It was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula. \[Breslow NE, Day NE. Statistical methods in cancer research: volume II, the design and analysis of cohort studies. IARC Sci Publ 1987;82:1-406.\]

  From peripheral stem cell infusion (Day0 ASCT) to death due to any cause, assessed up to 5 years

• 5-Year Disease-free Survival (Phase II)

  Disease-free survival (DFS) was defined as time from peripheral stem cell infusion to relapse or death. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works. Disease-free survival was estimated using the Kaplan-Meier method; the 95% confidence interval was calculated using Greenwood's formula \[Breslow NE, Day NE. Statistical methods in cancer research: volume II, the design and analysis of cohort studies. IARC Sci Publ 1987;82:1-406.\]

  From peripheral stem cell infusion (Day0 ASCT) to first observation of relapse or death due to any cause, whichever comes first, assessed up to 5 years

Study Arms (2)

Zevalin 1000 cGy + VP-16 40 mg/kg + Cytoxan 100 mg/kg

EXPERIMENTAL

* Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10\^6 /kg) proceed to radioimmunotherapy. * Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation. * Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV * AHSCT: Patients undergo reinfusion of PBSCs. * Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity.

Biological: filgrastim; Drug: cyclophosphamide; Drug: etoposide; Procedure: AHSCT; Radiation: yttrium Y 90 ibritumomab tiuxetan

Zevalin 1000 cGy + VP-16 60 mg/kg + Cytoxan 100 mg/kg

EXPERIMENTAL

* Preparation for AHSCT: Peripheral blood stem cells (PBSCs) are collected via leukapheresis. Samples are analyzed by cytogenetic studies, immunophenotyping, and gene rearrangement. Patients with an adequate number of collected CD34-positive cells (≥ 3 times 10\^6 /kg) proceed to radioimmunotherapy. * Radioimmunotherapy: Patients receive yttrium Y 90 ibritumomab tiuxetan and undergo bone marrow biopsy and dose estimation. * Chemotherapy: Patients receive etoposide IV and cyclophosphamide IV * AHSCT: Patients undergo reinfusion of PBSCs. * Growth factor therapy: Patients receive filgrastim (G-CSF) IV. Treatment continues in the absence of disease progression or unacceptable toxicity.

Biological: filgrastim; Drug: cyclophosphamide; Drug: etoposide; Procedure: AHSCT; Radiation: yttrium Y 90 ibritumomab tiuxetan

Interventions

filgrastim BIOLOGICAL

Zevalin 1000 cGy + VP-16 40 mg/kg + Cytoxan 100 mg/kg; Zevalin 1000 cGy + VP-16 60 mg/kg + Cytoxan 100 mg/kg

cyclophosphamide DRUG

Also known as: Cytoxan

Zevalin 1000 cGy + VP-16 40 mg/kg + Cytoxan 100 mg/kg; Zevalin 1000 cGy + VP-16 60 mg/kg + Cytoxan 100 mg/kg

etoposide DRUG

Also known as: VP-16

Zevalin 1000 cGy + VP-16 40 mg/kg + Cytoxan 100 mg/kg; Zevalin 1000 cGy + VP-16 60 mg/kg + Cytoxan 100 mg/kg

AHSCT PROCEDURE

Also known as: autologous hematopoietic stem cell transplantation

Zevalin 1000 cGy + VP-16 40 mg/kg + Cytoxan 100 mg/kg; Zevalin 1000 cGy + VP-16 60 mg/kg + Cytoxan 100 mg/kg

yttrium Y 90 ibritumomab tiuxetan RADIATION

Also known as: Zevalin

Zevalin 1000 cGy + VP-16 40 mg/kg + Cytoxan 100 mg/kg; Zevalin 1000 cGy + VP-16 60 mg/kg + Cytoxan 100 mg/kg

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

DISEASE CHARACTERISTICS: * Biopsy proven diagnosis of low- or intermediate-grade\* non-Hodgkin lymphoma (NHL) including any of the following: * Follicular small cleaved * Follicular mixed * Follicular large cell * Diffuse small cleaved * Diffuse mixed * Diffuse large cell * Immunoblastic (working formulation B, C, D, E, F, G and H) NOTE: \*A new classification scheme for adult non-Hodgkin lymphoma has been adopted by PDQ. The terminology of "indolent" or "aggressive" lymphoma will replace the former terminology of "low-", "intermediate-", or "high-" grade lymphoma. However, this protocol uses the former terminology. * Mantle cell and transformed low-grade lymphomas allowed * Demonstrated monoclonal CD20-positive B-cell population in lymph nodes and/or bone marrow * Favorable biodistribution on imaging dose * Patient either relapsed after achieving a complete (CR) or partial response (PR) to prior therapy, never responded to prior therapy, or has poor-risk disease * Sensitivity of disease based on 1 of the following: * Induction failure: patients who did not achieve a CR or PR from induction chemotherapy * Resistant relapse: patients who did not achieve a CR or PR from the most recent standard salvage chemotherapy * Sensitive relapse: patients who did achieve a CR or PR from the most recent standard salvage chemotherapy * Poor-risk disease defined as any of the following: * Age-adjusted International Prognostic Index (IPI) High- (3 risk factors) or High-Intermediate (2 risk factors) based on the following risk factors: * Stage III-IV disease * Elevated serum lactate dehydrogenase level * ECOG performance status 2-4 * Patients with aggressive NHL including mantle cell lymphoma and who required 2 different induction chemotherapy regimens to achieve a CR/PR * Patients with B-cell NHL and who failed to achieve a CR after adequate induction chemotherapy regimen(s) * Patients must have bone marrow aspiration and biopsy within 42 days before salvage chemotherapy or stem cell collection which show ≤ 10% lymphomatous involvement of total cellularity * Normal cytogenetic study on bone marrow (prior to salvage chemotherapy or stem cell collection) * Cytogenetic study on peripheral blood is acceptable if bone marrow biopsy has already been done and shows no sign of myelodysplastic syndrome (MDS) or lymphoma and a repeat bone marrow is deemed unnecessary by attending physician * No active or prior history of CNS diseases * No human anti-mouse antibody (HAMA) or human anti-chimeric antibody PATIENT CHARACTERISTICS: * ECOG performance status (PS) 0-1 or Karnofsky PS 80-100% * Platelet count normal * Serum creatinine ≤ 1.5 mg/dL or creatinine clearance ≥ 60 mL/min * FEV\_1 \> 65% of predicted or DLCO ≥ 50% of predicted * LVEF \> 50% by ECHO or MUGA scan * Bilirubin ≤ 1.5 times normal * SGOT or SGPT ≤ 2 times normal * HIV antibody-negative * No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, adequately treated noninvasive carcinoma, or other cancer from which the patient has been disease-free for at least five years * No active evidence of hepatitis B or C infection * No hepatitis B surface antigen positivity * No history of alcohol abuse * Body weight ≤ 250 pounds PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Patients who have received involved field external beam therapy to area excluding lung, heart, liver and kidney are allowed, but will be evaluated on a case-by-case basis * Patients must have recovered from last therapy and should be at least four weeks from prior radiation or chemotherapy * No prior radioimmunotherapy * No prior bone marrow transplantation

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

• City of Hope Medical Center: lead
• National Cancer Institute (NCI): collaborator

MeSH Terms

Conditions

Lymphoma; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, Large-Cell, Immunoblastic; Lymphoma, Mantle-Cell

Interventions

Filgrastim; Cyclophosphamide; Etoposide; ibritumomab tiuxetan

Condition Hierarchy (Ancestors)

Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Lymphoma, B-Cell

Intervention Hierarchy (Ancestors)

Granulocyte Colony-Stimulating Factor; Colony-Stimulating Factors; Glycoproteins; Glycoconjugates; Carbohydrates; Hematopoietic Cell Growth Factors; Cytokines; Intercellular Signaling Peptides and Proteins; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors; Phosphoramide Mustards; Nitrogen Mustard Compounds; Mustard Compounds; Hydrocarbons, Halogenated; Hydrocarbons; Organic Chemicals; Phosphoramides; Organophosphorus Compounds; Podophyllotoxin; Tetrahydronaphthalenes; Naphthalenes; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Polycyclic Compounds; Glucosides; Glycosides

Results Point of Contact

• Title: Dr. Auayporn Nademanee
• Organization: City of Hope National Medical Center

ANademanee@coh.org

626-256-4673

Study Officials

• Auayporn P. Nademanee, MD

  City of Hope Comprehensive Cancer Center

  STUDY CHAIR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 22, 2007
• First Posted: November 26, 2007
• Study Start: May 16, 2000
• Primary Completion: May 21, 2018
• Study Completion: May 21, 2018
• Last Updated: June 18, 2021
• Results First Posted: June 18, 2021

Record last verified: 2021-02